An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII

Oncogene

Volumn 33, Issue 33, 2014, Pages 4253-4264

  Li, L ^a   Chakraborty, S ^a   Yang, C R ^b   Hatanpaa, K J ^a   Cipher, D J ^c   Puliyappadamba, V T ^a   Rehman, A ^a   Jiwani, A J ^a   Mickey, B ^a   Madden, C ^a   Raisanen, J ^a   Burma, S ^a   Saha, D ^a   Wang, Z ^d   Pingle, S C ^e   Kesari, S ^e   Boothman, D A ^b   Habib, A A ^a,b,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

activation; dimerization; EGFR wild type; EGFRvIII; glioblastoma; HB EGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CARCINOGENICITY; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR 8 GENE; FEED FORWARD LOOP; GENE ACTIVATION; GENE SILENCING; GENE STRUCTURE; GENETIC REGULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE; ORTHOTOPIC TRANSPLANTATION; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84906221718     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.400     Document Type: Article

References (43)

1. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006; 11: 152-164. (Pubitemid 43261762)
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
3. Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalphastimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011; 121: 4670-4684.
4. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313: 144-147. (Pubitemid 15192341)
5. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009; 2: re6.
6. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024. (Pubitemid 41609094)
7. Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012; 2: 450-457.
8. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012; 2: 458-471.
9. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-7731. (Pubitemid 24238258)
10. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-5086. (Pubitemid 26374452)
11. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998; 12: 3675-3685. (Pubitemid 29019648)
12. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 2009; 106: 2712-2716.
13. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 2010; 464: 783-787.
14. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996; 13: 85-96. (Pubitemid 26248548)
15. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272: 2927-2935. (Pubitemid 27053343)
16. Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW et al. The tumorspecific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 2004; 23: 6095-6104. (Pubitemid 39178862)
17. Hwang Y, Chumbalkar V, Latha K, Bogler O. Forced dimerization increases the activity of DeltaEGFR/EGFRvIII and enhances its oncogenicity. Mol Cancer Res 2011; 9: 1199-1208.
18. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006; 66: 867-874. (Pubitemid 43165952)
19. Inda MD, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745.
20. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 2004; 3: 459-463. (Pubitemid 39193723)
21. Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R et al. Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer 2003; 104: 19-27. (Pubitemid 36184143)
22. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
23. Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 2008; 37: 353-373.
24. Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep 2005; 6: 942-948. (Pubitemid 41521949)
25. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763-773. (Pubitemid 35283965)
26. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010; 116: 815-818.
27. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290. (Pubitemid 47574858)
28. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 2007; 104: 12867-12872. (Pubitemid 47255246)
29. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009; 11: 448-458.
30. Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M et al. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Cancer Res 2011; 71: 7198-7206.
31. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 2007; 13: 1911-1925. (Pubitemid 46952962)
32. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N et al. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol (Berl) 1998; 96: 322-328. (Pubitemid 28451136)
33. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen Jr. MB. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 1989; 134: 894-902.
34. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004; 14: 131-136. (Pubitemid 38656384)
35. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor (EGFR) in glioma: Signal transduction, neuropathology, imaging and radioresistance. Neoplasia 2010; 12: 675-684.
36. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004; 21: 53-56. (Pubitemid 39518146)
37. Del Vecchio CA, Giacomini CP, VogelH, Jensen KC, Florio T, Merlo A et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 2012; 32: 2670-2681.
38. Ramnarain DB, Paulmurugan R, Park S, Mickey BE, Asaithamby A, Saha D et al. RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ 2008; 15: 344-353.
39. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995; 6: 1251-1259.
40. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60: 3081-3087. (Pubitemid 30395838)
41. Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol 2011; 102: 353-366.
42. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 2005; 65: 5221-5230. (Pubitemid 40827332)
43. Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B et al. Opposing effect of EGFRwt on EGFRvIII mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Reports 2013; 4: 764-775.